Krsnaa did not disclose the size of the deal, the investment will be fully funded through internal accruals over the next two to three months.

Krsnaa Diagnostics has acquired a 23.53% stake in Apulki Healthcare, India’s first public-private partnership (PPP) dedicated to cancer and cardiac care hospitals. 

According to a company statement, the acquisition strengthens Krsnaa’s position in providing comprehensive diagnostic services for cancer and cardiac patients under one roof.

Krsnaa Diagnostics, known for its broad range of diagnostic services, plans to utilize this acquisition to deliver integrated diagnostic services directly to patients undergoing cancer and cardiac treatments. 

The investment aligns with the company's goal of expanding its service offerings in specialized medical fields where early and accurate diagnostics are crucial.

Krsnaa Diagnostic’s Expansion Plans

Yash Mutha, Joint Managing Director at Krsnaa Diagnostics, highlighted the strategic significance of the investment, saying, "This investment is more than just a strategic partnership; it is a game-changer in the Indian healthcare landscape. By acquiring a stake in Apulki, we are positioning ourselves at the forefront of the rapidly expanding cancer and cardiac care segment."

The acquisition will enable Krsnaa to offer diagnostic services to hospital patients and retail clients, broadening its reach in urban areas. 

Further, the company sees this partnership as a critical move to meet the growing demand for specialized diagnostics in India, particularly in oncology and cardiology.

"This partnership also marks a significant milestone for Krsnaa on the retail front, as it enables us to establish comprehensive diagnostic centres in premium urban locations. Through this collaboration, we will not only serve the captive patients within the hospitals but also cater to the growing number of retail patients seeking advanced diagnostics in these urban areas,"  Mutha said. 

While Krsnaa did not disclose the size of the deal, the investment will be fully funded through internal accruals over the next two to three months, ensuring that it does not strain the company’s cash flow. 

The deal is subject to the fulfillment of certain conditions, with definitive documents yet to be signed.

"It is important to note that this investment will not strain our cash flows, as it will be funded entirely through internal accruals over the next two to three months," Mutha added.

The company plans to set up diagnostic centers within Apulki Healthcare's facilities, catering to in-house and walk-in patients. 

This move is expected to enhance Krsnaa's footprint in premium urban locations, allowing the company to serve more patients with advanced diagnostic needs.

Stay tuned for more such updates on Digital Health News.